Reviva Pharmaceuticals Holdings Dividend

Dividend criteria checks 0/6

Reviva Pharmaceuticals Holdings does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.4%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$1.41
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely

Aug 24

We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Dec 28

Reviva Pharmaceuticals drops 9% on $8.5M private placement

Sep 06

We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Aug 24

Reviva Pharmaceuticals Q2 GAAP loss per share widens

Aug 15

Reviva reports positive brilaroxazine results in Aacute Schizophrenia

Apr 26

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if RVPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RVPH's dividend payments have been increasing.

Dividend Yield vs Market

Reviva Pharmaceuticals Holdings Dividend Yield vs Market

How does RVPH dividend yield compare to the market?
Segment	Dividend Yield
Company (RVPH)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Pharmaceuticals)	2.4%
Analyst forecast in 3 Years (RVPH)	n/a

Notable Dividend: Unable to evaluate RVPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RVPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate RVPH's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RVPH has not reported any payouts.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Reviva Pharmaceuticals Holdings Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals Holdings, Inc. announced delayed annual 10-K filing

New minor risk - Market cap size

New minor risk - Profitability

Insufficient new directors

Forecast to breakeven in 2026

Reviva Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $30.000008 million.

Reviva Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $30.000008 million.

Reviva Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $30.000008 million.

New major risk - Negative shareholders equity

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

New major risk - Share price stability

New minor risk - Market cap size

Reviva Pharmaceuticals Holdings, Inc., Annual General Meeting, Nov 13, 2023

New minor risk - Profitability

Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely

Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Completion for Pivotal Phase 3 Recover Study for Brilaroxazine in Schizophrenia

New minor risk - Market cap size

Reviva Pharmaceuticals Holdings, Inc. Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia

We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Reviva Pharmaceuticals Holdings, Inc. Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine

Price target increased to US$14.00

Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 Recover Study Evaluating Brilaroxazine for Schizophrenia

Reviva Pharmaceuticals Holdings, Inc., Annual General Meeting, Nov 10, 2022

Chief Financial Officer recently bought US$83k worth of stock

Reviva Pharmaceuticals drops 9% on $8.5M private placement

We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Reviva Pharmaceuticals Q2 GAAP loss per share widens

Reviva Pharmaceuticals Holdings, Inc. Provides Update on Clinical Development Pipeline

Chief Financial Officer recently bought US$61k worth of stock

Reviva Pharmaceuticals Holdings, Inc. Announces Resignation of Marc Cantillon as Chief Medical Officer, Effective July 5, 2022

Reviva Pharmaceuticals Holdings, Inc. Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia

Price target decreased to US$10.33

Reviva Pharmaceuticals Holdings, Inc. Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia

Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia

Price target decreased to US$13.00

Reviva Pharmaceuticals Holdings, Inc. Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia

Reviva reports positive brilaroxazine results in Aacute Schizophrenia

Reviva Pharmaceuticals Holdings, Inc. Announces Management Changes

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies